window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Biologics

  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Development,Regulatory Affairs,Supply Chain & Logistics

    Symbiosis completes 1,000th batch of sterile injectable drug product

    Contract manufacturer Symbiosis Pharmaceutical Services has announced the completion of [...]

    July 31, 2025
  • Artificial Intelligence,Biologics & Biosimilars,CDMOs & Manufacturing,Partnerships & Funding,Research & Development,Technology and platforms

    AI-powered bioreactor project aims to transform biologics manufacturing

    A Canada–UK collaboration is developing an AI-driven bioreactor platform designed [...]

    July 25, 2025
  • Biologics & Biosimilars,Drug Development,Oncology,Research & Development

    Why immunotherapy sometimes fails: Study reveals unintended effects of antibody design

    A new study from researchers in Japan has uncovered a [...]

    July 24, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Delivery & Formulation,Partnerships & Funding

    Stevanato Group secures €200 million to support global capacity expansion for drug delivery solutions

    Stevanato Group has secured €200 million in financing to support [...]

    July 30, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Clinical Development,Drug Development,Technology and platforms

    Solvias expands US cGMP testing capabilities with RTP center phase 2 build-out

    Solvias has achieved Current Good Manufacturing Practice (cGMP) readiness at [...]

    July 22, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Cell & Gene Therapy,Market Access & Commercialization

    Lonza upgrades CDMO outlook following strong H1 2025 performance

    Lonza has raised its full-year 2025 guidance for its contract [...]

    July 25, 2025
  • CDMOs & Manufacturing,Drug Development,Movers & Shakers

    Abzena appoints Geoffrey Glass as CEO to drive next growth phase

    Abzena, the integrated CDMO and CRO specializing in complex biologics [...]

    July 22, 2025
  • Biologics & Biosimilars,Clinical Development,Patient Centricity,Regulatory Affairs

    NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure

    Mirikizumab is now recommended by NICE for routine NHS use [...]

    July 14, 2025
  • Biologics & Biosimilars,Clinical Trials,Drug Development,Rare Diseases

    Eleva doses first volunteers with new therapy targeting rare kidney disease

    Dosing of CPV-104 in healthy volunteers marks key milestone in [...]

    July 7, 2025
  • CDMOs & Manufacturing,Drug Delivery & Formulation

    Inside Biosynth’s bold Berlin bet on bioconjugation

    The new cleanroom suite boosts GMP capabilities to support conjugated [...]

    July 3, 2025
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Chemify founder publishes three papers on programmable chemistry and automated drug discovery
    Categories: Artificial Intelligence, Drug discovery, Research & Development, Technology and platforms
  • European liver experts highlight rising MASLD burden at EASL symposium in Budapest
    Categories: Clinical studies, Gastroenterology, Healthcare leadership, Liver disease, Metabolic Diseases
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top